

Supplementary File S2: Baseline and clinical characteristics comparison after classifying the study population based on HBV vaccine response.

	Adequate response (≥ 10-99, n=65)	Effective response (≥ 100 n=53)	p-value
Age (Mean \pm S.D)	34.1 \pm (12.1)	34.7 \pm (12.5)	0.806
BMI (Mean \pm S.D)	26.2 \pm (5.4)	24.7 \pm (4.5)	0.093
Gender, N (%)			0.765
Male	35.0 (53.8%)	30.0 (56.6%)	
Female	30.0 (46.2%)	23.0 (43.4%)	
Smoking, N (%)			0.638
Smoker	9.0 (13.8%)	9.0 (17.0%)	
Non-Smoker	56.0 (86.2%)	44.0 (83.0%)	
UC Type, N (%)			0.762
E1	9.0 (13.8%)	5.0 (9.4%)	
E2	22.0 (33.8%)	19.0 (35.8%)	
E3	34.0 (52.3%)	29.0 (54.7%)	
Inflammatory markers (Mean \pm S.D)			0.373
Albumin, g/L	49 \pm (6.4)	43 \pm (5.8)	
CRP, mg/L	6.0 \pm (4.5)	5.8 \pm (4.4)	
Stool fecal calprotectin, ug/g	113 \pm (12.0)	111 \pm (11.7)	